不同益生菌补充剂对三重杆菌杆菌根除的比较有效性:一个网络元分析
Yue Wang1, Xue Wang1, Xue-Yan Cao1
1Medical Centre for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Frontiers in cellular and infection microbiology
|May 31, 2023
概括
将益生菌添加到标准的三重疗法可以显著提高Helicobacter pylori根除率. 两种Bifidobacterium-Lactobacillus和Bifidobacterium-Lactobacillus-Saccharomyces疗法为H. pylori感染提供了最佳的疗效和安全平衡.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 基于证据的医学基于证据的医学.
背景情况:
- 益生菌被认为是 Helicobacter pylori 根除的潜在辅助剂.
- 对于各种益生菌补充剂在H. pylori治疗中的比较有效性数据仍然有限.
研究的目的:
- 进行网络元分析,比较不同益生菌补充剂的有效性,与标准的H. pylori根除三重疗法一起使用.
- 根据根除疗效和副作用发生率对益生菌疗法进行排名.
主要方法:
- 在PubMed,Embase和Cochrane图书馆数据库中系统搜索随机对照试验,直到2022年4月.
- 34项符合条件的试验的贝叶斯网络元分析,涉及10种疗法中的9004名患者.
- 益生菌补充剂的排名使用累积排名表面和对影响因素的子组分析.
主要成果:
- 大多数益生菌辅助疗法与单独的标准三重疗法相比,显示出更好的结果.
- 双菌-乳杆菌 (78.3%的根除) 和双菌-乳杆菌-Saccharomyces (88.2%的根除) 辅助疗法显示出显著的益处与低副作用.
- 优化益生菌的使用 (组合,时间,持续时间) 增强了H. pylori感染个体的治疗效果.
结论:
- 益生菌补充剂增强了H. pylori根除率,并在三重治疗中使用时提供保护作用.
- 双菌-乳杆菌或双菌-乳杆菌-Saccharomyces疗法代表了改善H. pylori根除结果的有利选择.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
467
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
467
Peptic Ulcer Disease IV: Management
118
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
118
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
477
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
477
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
161
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
161
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
526
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
526
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
474
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
474


